-
‘Our next target is anticancer drug,’ Handok chairman says
16 Feb 2023 07:41 GMT
… introduce Novartis’ new products (Onbrez, Xoterna, Enerzair, and … drugs, Pemigatinib and Tafasitamab.
“Handok’s weakness as a pharmaceutical … development (of new anticancer drugs). "
Handok has … ) treatment from Alexion Pharmaceutical, and growing it to …
-
Handok to market Novartis' respiratory drugs in Korea
21 Dec 2022 04:59 GMT
Handok and Novartis Korea signed a 2023 sales contract for three additional types of the latter's respiratory treatments in Korea.
Handok was in charge of domestic sales of Onbrez in 2013, and with this contract, it will be in charge of distribution, …
-
Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023 | Evolving Opportunities with AstraZeneca and Boehringer Ingelheim | Technavio
06 Jan 2020 22:33 GMT
… chronic obstructive pulmonary disease (COPD) drugs market 2019-2023 (Graphic: Business … . UTIBRON NEOHALER, SEEBRI NEOHALER, and ONBREZ BREEZHALER are some of the … of the company.
Teva Pharmaceutical
Teva Pharmaceutical operates the business across segments …
-
Delhi HC upholds order restricting sale of Cipla's respiratory disease drug
09 Mar 2017 18:17 GMT
… from selling its respiratory disease drug – Indaflo. Cipla had … Novartis’s own variant – Onbrez. After winning the first … Onbrez.
The counsels had also highlighted that Novartis imported the drug … foundation of innovative drug discovery and essential to …
-
Delhi HC bars Cipla from selling Novartis’ respiratory drug
09 Mar 2017 15:08 GMT
… of Novartis AG’s respiratory drug Onbrez in India, upholding the … under the trademark name of Onbrez through its licencee Lupin … Novartis, claiming that the pharma firm was not working the … are the foundation of innovative drug discovery and essential to …